Findings
========

Although eating a late-evening meal (ELM) is likely to be an unhealthy behavior that may cause postprandial hyperglycemia and decrease the metabolic rate \[[@B1]-[@B3]\], the physiological and clinical relevance of ELM is poorly understood. In our previous studies, low serum amylase was associated with obesity, type 2 diabetes, metabolic syndrome, and non-alcoholic fatty liver disease \[[@B4],[@B5]\]. Therefore, we investigated whether ELM was associated with low serum amylase and other unhealthy conditions or eating behaviors in 2,426 asymptomatic adults.

The subjects were asymptomatic adults aged 20--80 years who lived in Saitama, Japan, and underwent thorough medical checkups at Social Insurance Omiya General Hospital, Saitama, Japan. This study was conducted using data collected between 2009 and 2010. The protocol was approved by the Ethics Committee of Josai University, and informed consent was obtained from all participants. Subjects with suspected acute pancreatitis (serum amylase \>200 IU/l), very low serum amylase (\<30 IU/l), or suspected renal failure were excluded from the study. Subjects completed a questionnaire, which was developed by the Japanese Ministry of Health, Labour and Welfare in 2007 to prevent metabolic syndrome and cardiovascular diseases \[[@B6]\]. Suspected ELM, skipping breakfast, and rapid eating were determined using the questions, "Do you eat a late-evening meal within 2 hour before bedtime at least three times per week?", "Do you skip breakfast at least three times per week?", and "Do you think your meal-eating speed is usually rapid compared with other people's?", respectively, for which the available responses were yes or no.

Anthropometric and laboratory tests were conducted after an overnight fast. Serum parameters were measured using an autoanalyzer (Hitachi, Tokyo, Japan). Serum amylase levels were measured using an enzymatic method (L-type Amylase; Wako, Tokyo, Japan) with a normal range of 41--112 IU/l. We defined low serum amylase as \<60 IU/l, as previously described \[[@B5]\]. HbA1c was converted to National Glycohemoglobin Standardization Program levels \[[@B7]\].

Table  [1](#T1){ref-type="table"} shows the clinical characteristics of the subjects. Overall, subjects who reported ELM were younger, which likely affected the less proportion of dyslipidemia, more frequently males, smokers, and daily alcohol consumers, had a higher body mass index, and frequently reported unhealthy eating behaviors. Multivariate logistic regression analysis showed that ELM was independently associated with low serum amylase and common unhealthy behaviors (Table  [2](#T2){ref-type="table"}, Model 4). However, elevated fasting plasma glucose and HbA1c (≥6.5%) were not significantly associated with ELM. These latter results suggest that ELM is not directly associated with impaired glucose metabolism, even though plasma glucose levels were transiently increased after a single late-evening meal and subsequent breakfast \[[@B8]\]. When the associations of low serum amylase with self-reported skipping breakfast and rapid eating were examined, no significant association was observed after adjustment for confounders listed in Table  [2](#T2){ref-type="table"} Model 4 \[odds ratio (95% CI), 1.20 (0.94-1.54), P = 0.15 and 0.99 (0.81-1.22), P = 0.96, respectively\].

###### 

Subject characteristics

                                               **ELM**       **P value**   
  ----------------------------------------- -------------- --------------- -----------
  N                                             1,621            805             
  Men, (%)                                       56.8           82.6        \< 0.0001
  Age                                        56.0 ± 11.8     48.8 ± 10.7    \< 0.0001
  BMI (kg/m^2^)                               22.9 ± 3.1     24.0 ± 3.4     \< 0.0001
  Systolic blood pressure (mmHg)              122 ± 18.8     120 ± 18.9       0.18
  Diastolic blood pressure (mmHg)            75.4 ± 12.5     76.1 ± 13.1      0.16
  Triglyceride (mg/dl)                       91 (66--133)   101 (71--144)   \< 0.0001
  HDL-cholesterol (mg/dl)                    62.5 ± 14.8     57.9 ± 14.6    \< 0.0001
  FPG (mg/dl)                                 101 ± 18.5     102 ± 17.2       0.30
  HbA1c (%, NGSP)                             5.7 ± 0.6       5.6 ± 0.6      0.0005
  eGFR (ml/min/1.73 m^2^)                    75.2 ± 14.0     78.3 ± 13.1    \< 0.0001
  Serum amylase (IU/l)                       76.2 ± 23.8     69.2 ± 22.0    \< 0.0001
  Medications for                                                                
  Hypertension, n (%)                         293 (18.1)     118 (14.7)       0.03
  Diabetes, n (%)                              60 (3.7)       21 (2.6)        0.16
  Dyslipidemia, n (%)                         205 (12.6)      47 (5.8)      \< 0.0001
  Past history                                                                   
  Heart disease, n (%)                         29 (1.8)       12 (1.5)        0.59
  Stroke, n (%)                                65 (4.0)       20 (2.5)        0.05
  Current smoking, n (%)                      318 (19.6)     311 (38.6)     \< 0.0001
  Daily alcohol consumption, n (%)            419 (25.8)     339 (42.1)     \< 0.0001
  Regular exercise, n (%)                     605 (37.3)     166 (20.6)     \< 0.0001
  Self-reported skipping breakfast, n (%)     159 (9.8)      232 (28.8)     \< 0.0001
  Self-reported rapid eating, n (%)           406 (25.0)     313 (38.9)     \< 0.0001

Data are expressed as means ± SD, median (interquartile range), or *n* (%).

Differences in continuous and categorical variables between the two groups were examined using *t*-tests and χ^2^-tests, respectively, except for triglyceride, which was compared using the Mann--Whitney test.

eGFR was calculated as previously described \[[@B5]\].

BMI, body mass index; eGFR, estimated glomerular filtration rate; ELM, eating a late-evening meal; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; NSGP, National Glycohemoglobin Standardization Program.

###### 

Odds ratios of low serum amylase and other clinical variables for ELM

                                        **OR (95% CI)**    **P value**
  ----------------------------------- ------------------- -------------
           Low serum amylase                                     
                Model 1                1.86 (1.55--2.23)    \<0.0001
                Model 2                1.47 (1.20--1.79)     0.0002
                Model 3                1.41 (1.16--1.73)     0.0008
                Model 4                1.33 (1.08--1.63)      0.008
                  Men                                            
                Model 1                3.61 (2.94--4.44)    \<0.0001
                Model 4                2.28 (1.80--2.90)    \<0.0001
            Current smoking                                      
                Model 1                2.58 (2.14--3.11)    \<0.0001
                Model 4                1.28 (1.03--1.59)      0.03
        Daily alcohol drinking                                   
                Model 1                2.48 (2.01--3.05)    \<0.0001
                Model 4                1.83 (1.43--2.34)    \<0.0001
           Regular exercise                                      
                Model 1                0.44 (0.36--0.53)    \<0.0001
                Model 4                0.66 (0.53--0.83)     0.0004
    Overweight (BMI ≥25.0 kg/m^2^)                               
                Model 1                1.89 (1.57--2.29)    \<0.0001
                Model 4                1.38 (1.11--1.71)      0.004
   Self--reported breakfast skipping                             
                Model 1                3.72 (2.98--4.66)    \<0.0001
                Model 4                2.18 (1.70--2.80)    \<0.0001
      Self--reported rapid eating                                
                Model 1                1.90 (1.59--2.28)    \<0.0001
                Model 4                1.60 (1.30--1.96)    \<0.0001
       Elevated FPG (≥126 mg/dl)                                 
                Model 1                0.95 (0.67--1.36)      0.79
                Model 4                0.91 (0.58--1.43)      0.62
        Elevated HbA1c (≥6.5%)                                   
                Model 1                0.96 (0.68--1.35)      0.82
               Model 4\*               1.13 (0.71--1.79)      0.61

Model 1: unadjusted.

Model 2: adjusted for age (as a continuous variable), sex, and current smoking (versus non-smoking).

Model 3: Model 2 plus adjustment for medications (for hypertension, diabetes, and dyslipidemia), history of stroke or cardiovascular disease, daily alcohol consumption (versus infrequent/no alcohol consumption), and regular exercise (≥30 min exercise per session \>2 times/week versus infrequent exercise).

Model 4: Model 3 plus overweight (BMI ≥25.0 kg/m^2^; versus non-overweight, BMI \<25 kg/m^2^), self-reported skipping breakfast (yes versus no), self-reported rapid eating (versus normal or slow), eGFR (as a continuous variable), and elevated FPG (≥126 mg/dl; versus normal FPG, \<126 mg/dl).

\*Elevated FPG was not adjusted.

eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c.

In recent years, unfavorable eating behaviors, such as rapid eating and skipping breakfast, were reported to be associated with obesity and abnormal glucose metabolism \[[@B9]-[@B14]\]. The serum amylase level is proportional to the serum level of pancreatic amylase that leaks from pancreas into the blood \[[@B15],[@B16]\]. Because pancreatic amylase plays a key role in digestion, the serum amylase level reflects the state of digestion, particularly of carbohydrate. Theoretically, low levels of secreted amylase represent reduced absorption of carbohydrate, the predominant energy source in most meals, and may result in malnutrition and underweight. Unexpectedly, in our previous studies of asymptomatic adults, low serum amylase was associated with obesity and metabolic syndrome \[[@B4]\], which commonly reflect excess energy intake. Additionally, low levels of salivary amylase, which also contributes to the digestion of food \[[@B17]\], were observed in diabetic patients \[[@B18]\]. Hyperglycemia after a high-starch load occurred in healthy subjects with low salivary amylase \[[@B19]\]. Therefore, the associations among ELM, low serum amylase, and overweight are not inconsistent with these previous findings. A plausible explanation for the association is that low serum amylase may reflect an adaptive process to protect against prolonged hyperglycemia with regular ELMs and overweight.

Our study has several limitations. First, the quantity, type, and precise timing of the evening meal were not recorded. Second, the questionnaire used to assess eating behaviors has not been validated. However, the significant associations of ELM with other abnormal eating behaviors, particularly skipping breakfast and rapid eating, indicate that the simple question about ELM may be sufficient to suspect ELM and other abnormal eating behaviors. Nevertheless, the limited data and the design of the questionnaire could interfere with the observed associations. Third, other digestive enzymes such as lipase and trypsin were not measured in this study. Therefore, further studies are needed to confirm the current findings and to clarify the underlying mechanism and the causality in more detail.

In conclusion, the current results suggest that ELM is independently associated with low serum amylase and common unhealthy behaviors.
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